An­tios Ther­a­peu­tic­s' hep B can­di­date gets an­oth­er round of ap­plause from in­vestors, clos­ing out a $171M megaround

An­tios Ther­a­peu­tics, the At­lanta biotech that was the brain­child of for­mer hep C pi­o­neer Phar­mas­set ex­ec­u­tive and for­mer An­tios CEO Abel De La Rosa, an­nounced this morn­ing that the biotech raised $75 mil­lion in a Se­ries B-1, end­ing the firm’s Se­ries B round.

Af­ter the biotech threw its hat in­to the he­pati­tis B ring three years ago with $25 mil­lion from a Se­ries A, An­tios then raised $96 mil­lion from a Se­ries B in April to push their lead can­di­date — an ac­tive site poly­merase in­hibitor nu­cleotide, or AS­PIN known as ATI-2173 — through Phase II. The lat­est $75 mil­lion round brings the com­pa­ny’s Se­ries B up to $171 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER